Form 4: Sana Biotechnology Director Granted 80,000 Stock Options

Sana Biotechnology, Inc. Director Mary Agnes Wilderotter was granted 80,000 stock options with an exercise price of $2.55, vesting by June 2026.

Summary

• Mary Agnes Wilderotter, a Director of Sana Biotechnology, Inc. (SANA), was granted 80,000 stock options on June 5, 2025.
• Each option has an exercise price of $2.55 and was granted at a price of $0.00.
• The options are set to vest 100% on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders, contingent on continuous service.
• The stock options have an expiration date of June 4, 2035.
• Following this transaction, Ms. Wilderotter directly beneficially owns 80,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning interests. It is neither significantly positive nor negative, but slightly positive as it indicates continued commitment and incentivization of a key board member.

Positives

• The grant of stock options to a director, Mary Agnes Wilderotter, aligns her interests with those of shareholders, as the value of her compensation is tied to the company's stock performance.
• The options have a long expiration date (June 4, 2035), providing a significant window for the company's stock to appreciate.

Risks

• The value of the stock options is dependent on the future market price of Sana Biotechnology, Inc. common stock, which is subject to market fluctuations and company performance.
• The options are subject to a vesting schedule, meaning the director must provide continuous service until June 2026 (or the 2026 annual meeting) to fully realize the grant.

Future Outlook

The stock options are set to vest on the earlier of June 5, 2026, or immediately prior to the 2026 annual meeting of stockholders, contingent on Mary Agnes Wilderotter's continuous service to Sana Biotechnology, Inc.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and broader corporate sectors to incentivize long-term commitment and align leadership interests with shareholder value creation. This is a standard form of non-cash compensation for board members.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While the specific number of options (80,000) and exercise price ($2.55) would typically be benchmarked against peer companies (e.g., other clinical-stage biotech firms of similar market capitalization and development stage), this Form 4 does not provide sufficient data for a detailed comparative analysis.
• Generally, such grants aim to be competitive within the industry to attract and retain qualified board members.

Related Party Transactions

• This document details a related party transaction, specifically the grant of stock options as compensation to Mary Agnes Wilderotter, a director of Sana Biotechnology, Inc.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also serves to align the director's interests with shareholder value creation.
• Director (Mary Agnes Wilderotter): Receives equity-based compensation, incentivizing her continued service and contribution to the company's success.

Next Steps

• The vesting of the 80,000 stock options on the earlier of June 5, 2026, or immediately prior to Sana's 2026 annual meeting of stockholders, contingent on continuous service.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology, Executive Compensation